Patients receiving anticancer therapies are frequently prescribed complex and high-risk medication regimens, which at times can result in medication misadventures. The objective of this review was to assess the effect of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies, including patients undergoing radiotherapy.
Methods
A systematic review of original publications indexed in EMBASE, MEDLINE and Cochrane Library from June 2007 to June 2017. Eligible studies evaluated outpatient pharmacy clinic services for cancer patients and reported at least one medication-related quantitative outcome measure. Two authors independently reviewed full-text articles for inclusion, then extracted data and performed quality and risk of bias assessments.
Results
Of 908 identified publications, 13 met predefined eligibility criteria; 1 randomised control trial, 2 controlled cohort studies and 10 uncontrolled before–after studies. Many excluded studies described outpatient pharmacy services but lacked medication-related outcomes. All included studies had informative practice model designs, with interventions for drug-related problems including drug dose optimisation (n = 8), reduced drug interaction (n = 6) and adverse drug reaction reporting (n = 3). Most studies (n = 11) reported on symptom improvement, commonly nausea (n = 7) and pain (n = 5). Of four studies in radiotherapy cohorts, pharmacist involvement was associated with improved symptoms, satisfaction and wellbeing scores.
Conclusion
Few studies have objectively assessed outpatient pharmacy cancer services, even fewer in the radiotherapy settings. Although the results support these services, significant heterogeneity and bias in the study designs prohibit robust conclusions and further controlled trials are required.
BlancoAIChaoKSEl NaqaIet al.Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys2005; 62: 1055–1069.
2.
BrizelDMAlbersMEFisherSRet al.Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med1998; 338: 1798–1804.
3.
ChaoKSDeasyJOMarkmanJet al.A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys2001; 49: 907–916.
4.
EltingLSCooksleyCDChambersMSet al.Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys2007; 68: 1110–1120.
5.
EpsteinJBHongCLoganRMet al.A systematic review of orofacial pain in patients receiving cancer therapy. Support Care Cancer2010; 18: 1023–1031.
6.
De CastroGGuindaliniRS. Supportive care in head and neck oncology. Curr Opin Oncol2010; 22: 221–225.
7.
LeesJChanA. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol2011; 12: 1249–1257.
8.
BassanFPeterFHoubreBet al.Adherence to oral antineoplastic agents by cancer patients: definition and literature review. Eur J Cancer Care2014; 23: 22–35.
9.
PutsMTCosta-LimaBMonetteJet al.Medication problems in older, newly diagnosed cancer patients in Canada: how common are they? A prospective pilot study. Drugs Aging2009; 26: 519–536.
10.
LingaratnamSArandaSPearceTet al.A controlled before and after study to evaluate a patient and health professional partnership model towards effective medication reconciliation. J Oncol Pharm Pract2013; 19: 48–56.
11.
NkansahNMostovetskyOYuCet al.Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev2010; 7: Cd000336–Cd000336.
12.
ColomboLRPAguiarPMLimaTMet al.The effects of pharmacist interventions on adult outpatients with cancer: a systematic review. J Clin Pharm Ther2017; 42: 414–424.
13.
RabowMWSchancheKPetersenJet al.Patient perceptions of an outpatient palliative care intervention: “It had been on my mind before, but I did not know how to start talking about death…”. J Pain Symptom Manage2003; 26: 1010–1015.
14.
McCallinA. Interdisciplinary practice – a matter of teamwork: an integrated literature review. J Clin Nurs2001; 10: 419–428.
15.
StrasserFSweeneyCWilleyJet al.Impact of a half-day multidisciplinary symptom control and palliative care outpatient clinic in a comprehensive cancer center on recommendations, symptom intensity, and patient satisfaction: a retrospective descriptive study. J Pain Symptom Manage2004; 27: 481–491.
16.
IiharaHIshiharaMMatsuuraKet al.Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic. J Eval Clin Pract2012; 18: 753–760.
17.
SessionsJKValgusJBarbourSYet al.Role of oncology clinical pharmacists in light of the oncology workforce study. J Oncol Pract2010; 6: 270–272.
18.
MertenJAShapiroJFGulbisAMet al.Utilization of collaborative practice agreements between physicians and pharmacists as a mechanism to increase capacity to care for hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant2013; 19: 509–518.
19.
DanielsonBFairchildAPituskinE. Using a multidisciplinary team approach to perform multidimensional assessment of patients with brain metastases. Support Care in Cancer2009; 17: 1037–1037.
20.
KawaguchiTAzumaKYamaguchiTet al.Preferences for pharmacist counselling in patients with breast cancer: a discrete choice experiment. Biol Pharm Bull2014; 37: 1795–1802.
21.
SkledarSJDoedynsAYourichB. Building an outpatient cancer center pharmacy program across a tristate region. Am J Health Syst Pharm2015; 72: 126–132.
22.
HanyaMKannoYAkasakiJet al.Effects of communication skill training (CST) based on SPIKES for insurance-covered pharmacy pharmacists to interact with simulated cancer patients. J Pharm Health Care Sci2017; 3: 11–11.
23.
FernandesOBakerM. Can pharmacists collaborate with patients and interprofessional teams to reduce medication-related risk at interfaces of care and improve meaningful patient outcomes?J Pharm Pract Res2017; 47: 331–332.
24.
MekonnenABMcLachlanAJBrienJ-aE. Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis. BMJ Open2016; 6: e010003–e010003.
25.
NiederCDalhaugAPawinskiAet al.Palliative radiotherapy with or without additional care by a multidisciplinary palliative care team in patients with newly diagnosed cancer: a retrospective matched pairs comparison. Radiat Oncol2015; 10: 61–61.
26.
National Health and Medical Research Council. NHMRC levels of evidence and grades for recommendations for guideline developers, Canberra: National Health and Medical Research Council, 2009.
27.
GuyattGHOxmanADVistGEet al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008; 336: 924–926.
28.
HigginsJPTAltmanDGGøtzschePCet al.The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011; 343: d5928–d5928.
29.
BilandzicAFitzpatrickTRosellaLet al.Risk of Bias in systematic reviews of non-randomized studies of adverse cardiovascular effects of thiazolidinediones and cyclooxygenase-2 inhibitors: application of a new Cochrane risk of bias tool. PLoS Med2016; 13: e1001987–e1001987.
30.
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 25 April 2016).
MoherDShamseerLClarkeMet al.Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev2015; 4: 1–1.
33.
PituskinEFairchildADutkaJet al.Multidisciplinary team contributions within a dedicated outpatient palliative radiotherapy clinic: a prospective descriptive study. Int Radiat Oncol Biol Phys2010; 78: 527–532.
34.
ValgusJJarrSSchwartzRet al.Pharmacist-led, interdisciplinary model for delivery of supportive care in the ambulatory cancer clinic setting. J Oncol Pract2010; 6: e1–e4.
35.
FairchildAPituskinERoseBet al.The rapid access palliative radiotherapy program: blueprint for initiation of a one-stop multidisciplinary bone metastases clinic. Support Care Cancer2009; 17: 163–170.
36.
WalterCMellorJDRiceCet al.Impact of a specialist clinical cancer pharmacist at a multidisciplinary lung cancer clinic. Asia Pac J Clin Oncol2016; 12: e367–e374.
37.
EdwardsSJAbbottREdwardsJet al.Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic. J Pharm Pract2014; 27: 46–52.
38.
MaJDTranVChanCet al.Retrospective analysis of pharmacist interventions in an ambulatory palliative care practice. J Oncol Pharma Pract2016; 22: 757–765.
39.
RibedARomero-JimenezRMEscudero-VilaplanaVet al.Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction. Int J Clin Pharm2016; 38: 280–288.
40.
ReadHLaddsSRhodesBet al.The impact of a supplementary medication review and counselling service within the oncology outpatient setting. Br J Cancer2007; 96: 744–751.
41.
YennurajalingamSUrbauerDLCasperKLet al.Impact of a palliative care consultation team on cancer-related symptoms in advanced cancer patients referred to an outpatient supportive care clinic. J Pain Symptom Manage2011; 41: 49–56.
42.
Arakawa-TodoMYoshizawaTZennamiKet al.Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes. Anticancer Res2013; 33: 5043–5050.
43.
CaracuelFBanosUHerreraMDet al.Influence of pharmaceutical care on the delayed emesis associated with chemotherapy. Int J Clin Pharm2014; 36: 287–290.
44.
HansenEAPietkiewiczJMBlumBL. Evaluation of the feasibility and utility of a pharmacist-centered collaborative drug therapy management program for oncology-based symptom management. J Pharm Pract2016; 29: 206–211.
45.
LiekwegAWestfeldMBraunMet al.Pharmaceutical care for patients with breast and ovarian cancer. Support Care Cancer2012; 20: 2669–2677.
46.
MoriskyDEGreenLWLevineDM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care1986; 24: 67–74.
47.
BrueraEKuehnNMillerMJet al.The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care1991; 7: 6–9.
48.
Sterne JAC, Higgins JPT, Elbers RG, Reeves BC and the development group for ROBINSI. Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I): detailed guidance, updated 12 October 2016. Available from http://www.riskofbias.info (accessed 25 December 2017).
49.
PutsMTETuHATourangeauAet al.Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. Ann Oncol2014; 25: 564–577.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
